Understanding the structural and functional changes and biochemical pathomechanism of the cardiomyopathy-associated

Leila Rezaei Somee1, Anis Barati1, Mohammad Bagher Shahsavani2

  • 1Protein Chemistry Laboratory (PCL), Institute of Biochemistry and Biophysics (IBB), University of Tehran, Tehran, Iran.

Insights

The p.R123W mutation in alpha B-crystallin disrupts protein structure, reducing chaperone function and promoting amyloid aggregation, leading to hypertrophic cardiomyopathy.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Structural Biology

Background:

  • Alpha B-crystallin (αB-crystallin) is a small heat shock protein (sHSP) vital for maintaining lens transparency and cellular protection.
  • Mutations in αB-crystallin are linked to diseases like cataract and cardiomyopathy.
  • The p.R123W mutation in αB-crystallin has been implicated in causing cardiomyopathy.

Purpose of the Study:

  • To investigate the structural and functional consequences of the p.R123W mutation in human αB-crystallin.
  • To elucidate the molecular mechanisms by which this mutation contributes to hypertrophic cardiomyopathy (HCM).

Main Methods:

  • Recombinant expression of wild-type and p.R123W mutant human αB-crystallin in E. coli.
  • Purification using anion exchange chromatography.
  • Structural and functional characterization via spectroscopy (e.g., circular dichroism) and microscopy (AFM, TEM).

Main Results:

  • The p.R123W mutation significantly altered αB-crystallin's secondary, tertiary, and quaternary structures.
  • Mutant protein showed increased β-sheet content, larger oligomers, and reduced thermal stability.
  • The mutant protein exhibited diminished chaperone activity and a higher propensity for amyloid aggregate formation.
  • Structural changes impact interactions with cardiac proteins like calcineurin.

Conclusions:

  • The p.R123W mutation induces significant structural destabilization and aggregation of αB-crystallin.
  • These molecular changes provide a mechanistic explanation for the p.R123W mutation's role in hypertrophic cardiomyopathy.
  • Understanding these effects aids in developing therapeutic strategies for crystallin-associated heart conditions.